Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane.
Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane.
复制标题
可承受性和成本效益：在成本效益层面上做出决策。
作者：
P. Sendi;Andrew Briggs
最近的许多研究兴趣都集中在处理成本效益分析中的不确定性，特别是增量成本效益比（ICER）的置信区间的计算。 ICER 为负时的解释问题导致了两个重要且相关的发展：净效益统计的使用以及使用可接受性曲线在成本效益分析中呈现不确定性。然而，这些进展都没有直接解决决策者受到固定预算的限制，可能无法为新的、更昂贵的干预措施提供资金的问题，即使这些干预措施已被证明物有所值。针对这一限制，作者引入了“负担能力曲线”，它反映了一个项目在广泛的阈值预算范围内负担得起的概率。作者认为，干预措施负担得起且具有成本效益的联合概率对于决策更有用，因为它捕获了负责卫生服务预算的人员所面临的决策问题的两个维度。
Much recent research interest has focused on handling uncertainty in cost-effectiveness analysis and in particular the calculation of confidence intervals for incremental cost-effectiveness ratios (ICERs). Problems of interpretation when ICERs are negative have led to two important and related developments: the use of the net-benefit statistic and the presentation of uncertainty in cost-effectiveness analysis using acceptability curves. However, neither of these developments directly addresses the problem that decision-makers are constrained by a fixed-budget and may not be able to fund new, more expensive interventions, even if they have been shown to represent good value for money. In response to this limitation, the authors introduce the 'affordability curve' which reflects the probability that a programme is affordable for a wide range of threshold budgets. The authors argue that the joint probability an intervention is affordable and cost-effective is more useful for decision-making since it captures both dimensions of the decision problem faced by those responsible for health service budgets.
影响因子：
3.5
作者：
Garber, AM;Phelps, CE
通讯作者：
Phelps, CE
成本效益分析的统计方法。
DOI：
10.1016/s0197-2456(95)00259-6
发表时间：
1996
期刊：
Controlled clinical trials
影响因子：
--
作者：
Siegel,C;Laska,E;Meisner,M
通讯作者：
Meisner,M